Company Announcements - 2010
-
Form 604 - Notice of change of interests of substantial holder23 December 2010
-
Securities Trading Policy21 December 2010
In accordance with ASX Listing Rule 12.9 which comes into effect on 1 January 2011, attached is a copy of the securities trading policy of Analytica Limited that is contained in section 4 (Code of Conduct for Transactions in Securities) of the Company's Corporate Governance Charter.
-
Annual General Meeting 201018 November 2010
-
Form 604 - Notice of change of interests of substantial holder8 November 2010
-
Response to ASX Query5 November 2010
Response to ASX questions regarding the Company's Appendix 4C for the quarter ended 30 September 2010
-
Appendix 4C - Quarterly Cash Flow28 October 2010
Analytica presents its Appendix 4C for the quarter ended 30 September 2010.
-
Form 604 - Notice of change of interests of substantial holder22 October 2010
-
Notice of Annual General Meeting and Proxy Voting Form14 October 2010
The Annual General Meeting of Analytica Limited will be held at 10:00am (Brisbane time) on Thursday 18 November 2010 in the East Auditorium at Brisbane Technology Park Conference Centre, 1 Clunies Ross Court (off Miles Platting Road), Eight Mile Plains, Queensland. A copy of the Notice of Meeting and Proxy Form is attached to this announcement.
-
Annual Report (Print Copy)8 October 2010
AR formatted for print.
-
Annual Report30 September 2010
-
Change of Registered Office Address06 September 2010
Analytica advises that its registered office address has changed, effective immediately. Analytica's new registered office address is at the office of the Company Secretary. Analytica's principal place of business, telephone number and facsimile number remain unchanged.
-
Appendix 4E - Preliminary Final Report30 August 2010
-
Appendix 4C - Quarterly Cash Flow30 July 2010
Analytica presents its Appendix 4C for the quarter ended June 2010.
-
Appendix 4C - Quarterly Cash Flow27 April 2010
Analytica presents its Appendix 4C for the quarter ended March 2010.
-
Licensing and Distribution Agreement signed with Medical Australia13 April 2010Medical products manufacturer and distributor Medical Australia Limited (ASX: MLA), today announced that it has signed a licensing and distribution agreement with Analytica Limited (ASX: ALT), a leading Australian medical technology company focussing on the development and commercialisation of a range of medical devices and pharmaceutical implants.
-
Appendix 3B13 April 2010New issue announcement, application for quotation of additional securities and agreement.
-
Section 708A(5)(e) Notice13 April 2010
-
Change of Company Secretary1 April 2010The Analytica Board advises that Ben Graham has resigned as Company Secretary and Jennie Yuen has been appointed as Company Secretary of Analytica Limited, effective immediately.
-
Appendix 3B12 March 2010
New issue announcement, application for quotation of additional securities and agreement.
-
AutoStart Burette Recieves FDA 510(k) Clearance9 March 2010Analytica Ltd is pleased to announce receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the AutoStart Burette in the United States. This is a significant milestone in the commercialisation of the AutoStart Burette, opening up one of the world's most significant medical device market.
-
Appendix 3B2 March 2010New issue announcement, application for quotation of additional securities and agreement.
-
Form 6032 March 2010Notice of initial substantial holder
-
Appendix 4D - Half Yearly Report26 February 2010For the 6 months ended December 2009 (current period) and the previous corresponding period 6 months ended 31 December 2008
-
Market Update5 February 2010
Analytica Limited wishes to advise that it?s National Health & Medical Research Council (NHMRC) grant application has been unsuccessful. Analytica, in conjunction with Professor Paul Haber of the University of Sydney, applied for a NHMRC grant to partly fund the early stages of its Naltrexone implant program. Analytica is aiming to produce a TGA-approved Naltrexone implant for the treatment of drug and alcohol addiction. Currently, there is no generally available, TGA-approved implant to treat such addictions.
-
Appendix 4C - Quarterly Cash Flow29 January 2010
Analytica presents its Appendix 4C for the quarter ended 31 December 2009.
-
Appendix 3B22 January 2010
New issue announcement, application for quotation of additional securities and agreement.